BACKGROUND: Influenza is a major cause of morbidity and mortality worldwide. Following
Introduction
Acute respiratory infections constitute a major cause of morbidity and mortality globally.
(1) According to the updated 2004 World Health Organization (WHO) report, the death toll from acute lower respiratory infections caused by bacterial and viral infections reached 4.2 million and accounted for 7.2% of all deaths worldwide. (1, 2) Data from the Global Burden of Disease study estimated that the mortality rate from lower respiratory tract infections due to influenza reached 0.9 per 100,000 population in the WHO Middle East and North Africa (MENA) region and the hospitalization rate ranged from 100 to 299 per 100,000 population. (3) Influenza is a major cause of both influenza-like illness (ILI) and more importantly severe acute respiratory infection (SARI) across the globe. (4, 5) Several studies in different regions of the world have indicated that influenza is a significant underlying cause for hospitalization of patients with acute respiratory infection (ARI). (6) (7) (8) (9) Infection with influenza may manifest in a wide spectrum of illness levels ranging from asymptomatic infection to death. Different studies reported asymptomatic cases to account for 14% up to 77% of influenza infections. (10) (11) (12) The major cause for hospital admission due to influenza is the development of pneumonia, which could be either primary viral or secondary to bacterial co-infection, and acute respiratory distress syndrome. (13, 14) In severe cases of influenza infection, death may ensue even in the absence of comorbidities. (15) Annual seasonal influenza vaccination can reduce the chances of getting infected and subsequently prevent spread of the virus. Vaccines are available in two forms: the inactivated influenza vaccine (IIV), which is administered intramuscularly or intradermally, and the live attenuated influenza vaccine, administered intranasally, (LAIV). Vaccination is recommended by the Centers for Disease Control, USA, annually to everyone above 6 months of age and should be given before influenza season commences, usually during early fall or late summer. (16) However, in many countries, especially developing ones, there is a lack of data on the epidemiology of influenza disease leading to a lack of appreciation of its true burden by public health authorities and impeding the introduction of influenza vaccine on national vaccination schedules. Accordingly, the WHO recommended the generation of country-specific epidemiological data in order to identify high priority groups, emphasizing the inclusion of pregnant women, and the optimal timing of vaccination against influenza. (17) Given the epidemic nature of the illness, there has been an increasing interest in the burden resulting from its outbreaks in addition to concerns about its association with myocardial infarctions, glycemic variation in diabetic patients, and the exacerbation of other chronic illnesses. (1, (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) While data on the epidemiology and severity of this disease has been primarily obtained from studies in temperate developed countries, developing regions including the MENA region have also begun investigating this burden in their hospitals allowing the formation of more complete global data. (28) In Lebanon, the influenza burden of disease is unknown. Since 2008, surveillance of influenza virus among ILI patients at the American University of Beirut Medical Center (AUBMC), was performed at the Center for Infectious Diseases Research (CIDR). (29) (30) (31) (32) (33) The Ministry of Public Health started reporting influenza activity as part of its SARI surveillance since 2015. Whereas these surveillance programs furnish important information about influenza activity in Lebanon, they do not reflect the total burden of disease of influenza. In fact, an ideal study to look at the burden of influenza diseases would be population-based, prospective, and armed with a highly sensitive and specific test for influenza to be conducted both in outpatient and inpatient settings. However, such a study is not feasible and too expensive to conduct. An alternative approach that we chose was to conduct a retrospective review on laboratory-proven influenza at our center where both inpatient and outpatient services exist. The information collected from this review will be helpful in forming a better estimate about the burden of disease of influenza in Lebanon as extrapolated from our findings. This may help inform public policy about prevention of influenza infections.
Methods And Materials

Study design
This is a retrospective review of subjects who tested positive for influenza virus at AUBMC, a tertiary care medical center located in Beirut, Lebanon, between January 1, 2008 and June 30, 2016. Samples were collected from these subjects and tested for influenza A and B viruses by rapid diagnostic test and/or by real-time reverse-transcriptase polymerase chain reaction (RT-PCR). Information already collected for subjects diagnosed to have influenza A or B covering all the seasons from 2008 till 2016 who were previously enrolled in three ongoing surveillance studies at the CIDR at AUBMC were also included.
Sampling:
Samples were either taken by nasopharyngeal swab or nasal wash and tested directly (at bed side -as part of the ILI surveillance studies) using one of the rapid diagnostics test kits or were sent in sterile normal saline to AUBMC laboratory and tested within 24 hours. Deep tracheal aspirates were mostly used for testing patients who were intubated.
Storage: For those samples obtained from subjects participating in the IRB-approved surveillance studies since 2008, a second sample was taken (after obtaining consent) and was transported in virus transport media, stored at 4oC for no more than 24 hours or at -20oC if taken over the weekend. These samples were ultimately stored at -80 oC until their transfer to the Department of Public Health at Niigata University, Japan for multiplex polymerase chain reaction and viral culture.
Examination of samples:
Different rapid antigen detection kits were used across the different seasons. Polymerase chain reaction: real-time reverse-transcriptase (RT) polymerase chain reaction (PCR) using the GENEXPERT (Cepheid) platform was used at AUBMC Clinical Molecular Biology Laboratory. (33) 
Identification of subjects:
All subjects were identified retrospectively through medical records at AUBMC and through the parallel ILI surveillance studies for influenza conducted during the study period. These surveillance studies enrolled subjects with symptoms fitting the ILI case definition, presenting as outpatients or inpatients, and tested them for influenza using rapid diagnosis test (RDT) and then RT-PCR. The list of remaining subjects was retrieved by the medical coder by looking at the following lab codes: "8108" for rapid influenza A & B antigen detection and "8988" for Flu PCR. This was done through the Department of Pathology and Laboratory Medicine by sending a Statistical Information Request. Data from each chart was collected and recorded on a case report form (CRF). Medical records with the discharge diagnosis of influenza were also retrieved.
The CRF included information on demographic data (gender, age, residence, etc.), social history, medical history, influenza vaccination history, clinical symptoms, hospital course, severity parameters (O 2 requirement, intensive care admission, mechanical ventilation, complications), radiology findings, targeted laboratory results, samples dates, method of influenza detection, use of antibiotics/antivirals, hospital stay and outcomes.
Inclusion criteria:
Any patient regardless of age or hospital admission status who was tested for influenza using either nasal wash/swab followed by PCR or RDT, or by serology at AUBMC lab or who was enrolled in the surveillance studies conducted at CIDR during the time period extending from January 1, 2008 till June 30, 2016 was included in the initial subject count. To note that surveillance studies were interrupted 
Results
During the study period spanning 8 influenza seasons from January 1 st , 2008 till June 30 th , 2016, a total of 11288 subjects presented to AUBMC with a respiratory illness for which they were tested for influenza infection. Out of all subjects tested, 1829 subjects (16%) had a positive test result for influenza; 29.6% (542 influenza cases) were identified during the 2009 influenza pandemic. Of the 1829 positive cases, 1529 (84%) were caused by influenza A, 242 cases (13%) by influenza B, and 55 cases (3%) had co-infection with both types (type was not reported in three cases). During the 2009 pandemic, 97.6% of the infections were caused by influenza A and 2% were co-infected. However, subtyping was done for only 35 cases during the pandemic, of which 28 cases were caused by influenza A (H1N1)pdm09.
Demographic and clinical characteristics of the subjects
Of the 1829 cases, 916 (50.1%) cases were female and 72 cases were pregnant; 24% of female subjects in the childbearing age ( Table 1 ). Most of the subjects resided in Beirut and Mount Lebanon governorates (73%) reflecting the population served by our center.
Subjects were divided into 7 age groups: the highest proportion (22.5%) was for adults between 19 and 50 years old, while only 9.5% were below 2 years old. At least one underlying comorbidity was present in 45.8% of cases reviewed and 31% had two or more comorbidities. The most common underlying chronic disease among adults was cardiovascular diseases (33%), malignancy (15%) and diabetes mellitus (14.8%). However, in the younger age groups (< 19 years) the most common underlying chronic diseases were asthma (16%) and malignancy (10.4%). Data on the immunization status against influenza was available for 456 cases; 22.8% (104) of these subjects had received influenza vaccine in the past 12 months at the time of diagnosis with influenza infection.
The most common presenting symptoms were respiratory (96%) with cough constituting 91.5 % of these symptoms. Fever was present in 89% of cases; 78% of febrile subjects with data on highest temperature recorded had high-grade fever ≥ 39°C. Gastrointestinal symptoms were present in 33.7% including vomiting (47%), diarrhea (32%) and abdominal pain (29.6%). Myalgia was reported in 31 % of subjects. Other less common symptoms (13.6%) included conjunctivitis, otitis, neurological events, confusion and dizziness. Moderate to severe influenza was encountered in 591 cases (42%) with a significant Pvalue (<0.001) between different age groups. Almost half of the subjects below 5 years (50.5%) and above 50 years (51.6%) had moderate to severe disease while around a third (28%) of those 10 to 50 years did ( Table 2) . When comparing percentages of moderate to severe disease within each type of influenza detected, influenza B infection was associated with a slightly higher incidence (49.8%) of moderate to severe disease compared to influenza A infection (40.9%) (P-value = 0.054). and malignancy (0.043). There was no statistically significant difference in mortality among different age groups or types of influenza infection detected. However, when stepwise logistic regression was done, only the presence of a proven viral co-infection, bacterial co-infection, underlying neurological diseases or radiologically-confirmed pneumonia were found to be independent risk factors for increased mortality (Table 4 ). with laboratory-confirmed influenza infection. Only 102 (20.6%) of those who received antibiotics had a proven bacterial co-infection. A proven bacterial co-infection was considered in the presence of a positive culture. In fact, pneumonia cases accounted for 49% of antibiotic prescription though not all of these cases were proven to be bacterial.
Antivirals were prescribed for 821 subjects (68.8% of those with available data N = 1193) with laboratory-confirmed influenza. Oseltamivir was prescribed in 807 subjects while zanamivir was prescribed in the remaining 14 subjects. Table (5) describes the different characteristics of the subjects who received antiviral treatment. The majority of elderly subjects and children below 2 years of age received antiviral therapy. There was a statistically significant higher percentage of antiviral prescription among inpatients, pregnant females and those with comorbid conditions. were Yamagata and 2 were Shanghai lineage.
Characteristics of subjects with laboratory-confirmed influenza by virus type are illustrated in (Table 6 ). There was a significant variation in the incidence of each type of influenza virus through the different influenza seasons and among different age groups.
Mean hospital stay duration was significantly higher in those who were co-infected with both types of influenza (17 days vs 7 days). Co-infection with both A and B viruses was significantly associated with higher incidence of ICU admission. Antibiotic and antiviral prescription was similar for both types and for co-infection. Death was equally reported for both types of influenza viruses (P-value = 1). 
Influenza hospitalization rates
Overall influenza-associated hospitalization rate reached 26.6%. The annual influenzaassociated hospitalization rate was lowest during the 2009 pandemic season (6.8%) and
trended up gradually to reach the highest during 2016 (41%) (Figure 2 ). In addition, the monthly influenza-associated hospitalization rate was as low as 3% in July and reached almost 37% during January (Figure 3 ).
Discussion
Our results show that seasonal influenza causes a substantial burden in the Lebanese In his systematic review, 71 studies were included of which only one study was from Lebanon but included a very small sample size. (30) According to the WHO Global Epidemiological Surveillance Standards for Influenza, a standard age grouping into 6 groups is suggested for analysis (5) . We further subdivided the population into an additional 7th 'adolescent' age group (10-19 years) . Results from the SARI surveillance by the MOH showed a similar distribution, with higher positivity rates among those 15-49 years reaching 26% in the southern sentinel site and a positivity rate of 21% for those 5-15 years in the Beirut sentinel site. (35) In addition to surveying sicker hospitalized subjects, an additional explanation may be that these age groups are less likely to be vaccinated when compared to the very young and the very old. According to a cross-sectional review published in 2015, influenza vaccine uptake among Lebanese adults was only 27.6% during the 2014/2015 season. (37) In Lebanon, influenza vaccination is only recommended for subjects with a chronic medical condition, hospital healthcare workers and pilgrims. (38) The vaccination rate for our population reached 22.4%.
Unfortunately, we did not have vaccination data for most of our subjects and the majority of available data was for pediatric patients. It is important to recall that although influenza vaccines were thought to be mostly effective for children 2 years and older, recent data showed high vaccine efficacy reaching 60% in infants as young as 6 months (34, (39) (40) (41) (42) (43) .
Our analysis showed that all severity parameters, except for hospital and ICU stay duration, were highly present within two age groups: below 2 years and ≥ 65 years. These results demonstrate that extremes of age have a more severe course of disease including a higher mortality rate. Several recommending bodies consider these age groups at higher risk for severe disease and mortality and thus recommend early initiation of antiviral therapy and emphasize the importance of vaccination. (44, 45) Unfortunately, vaccination is not recommended for these age groups nor included in the national immunization program in Lebanon. (38) The presence of at least one co-morbidity, mainly cardiovascular diseases, asthma, malignancy and diabetes mellitus, in 71% of hospitalized patients and 31% of outpatients is worrisome especially with recent data on influenza being a trigger for exacerbation of these illnesses and vice versa. Several papers have showed an association between influenza infection and myocardial infarction, chronic obstructive pulmonary disease exacerbations and diabetic crises. (18, 23, 24, 27, 46, 47) This also means that at least half of the study population was at higher risk for severe influenza disease and outcome including death. (48) Several complications have been linked to influenza infection including both pulmonary and extra-pulmonary. Both bacterial and viral pneumonias are established complications of influenza infection and have been reported as an independent risk factor for increased severity and mortality. (49) (50) (51) Similarly, our review showed that radiologically confirmed pneumonia was an independent risk factor for increased mortality among hospitalized patients ( Table 4 ). It was the most common complication reported with highest incidence in older age groups > 50 years. We could not determine whether these were primary viral pneumonias or bacterial co-infection in most of the cases. Inflammatory markers including C-reactive protein and procalcitonin were not used regularly especially in outpatients, so we did not track them. Regardless, 89% of these cases received antimicrobial treatment according to the treating physician's judgment. Of these pneumonia cases, 16 (6.6%) progressed to acute respiratory distress syndrome (ARDS).
Our population also displayed a wide array of extra-pulmonary complications including myocardial infarction, encephalopathy, shock, renal failure and liver failure. These complications have been reported in several articles (52) (53) (54) (55) (56) (57) and interest in determining their real burden is increasing as these extra-pulmonary complications actually represent a significant burden related to influenza infection that is sometimes overlooked. (53) According to the global burden of diseases study, influenza accounted for 0.26% of all- reported that most of the region's countries had a primary peak between January and
March with no or barely noticeable secondary peaks. (76) According to the Lebanese SARI sentinel surveillance, the primary peak extended from January till mid of March.(35) This is consistent with our data, which shows that the influenza season starts by November-December and peaks during January and February. These results imply that vaccination should be administered between September and October of each year to ensure optimal protection.
Our study has several limitations. The most significant limitation is the fact that this data was collected retrospectively from chart review. We could not obtain accurate data on vaccination rates in addition to other missing or incomplete data. Another limitation is that all these cases reviewed were from a single center that, despite being a major tertiary medical center, cannot reflect the actual Lebanese burden of influenza. A third limitation is the fact that we included all laboratory proven influenza cases regardless of initial presentation symptoms or reason for admission. As a result, we could not calculate influenza-attributable SARI cases and we could not compare this to other published data.
Also, we did not exclude possible health-care associated infections, although they contribute to the burden of influenza. Moreover, mortality rate associated with influenza might not be accurate since we had no follow up data on outpatients and thus significant data was missing.
Conclusion
This study is a first attempt to estimate the burden of influenza in Lebanon including a large number of subjects. Despite being a retrospective review, results offer groundwork for further influenza research. Based on the results presented by our review, influenza causes a substantial number of hospitalizations annually in Lebanon with significant morbidity and mortality across all age groups. Even though we had incomplete data on vaccination, a rate of 22% is fairly low. Fortunately, there is an increased interest in influenza research and surveillance along with increased testing for ILI and SARI cases.The Influenza-associated hospitalization rate over the seasons Figure 3 Influenza-associated hospitalization rate by month
